Publication Topic

Chappell G, Rager J, Wolf J, Babic M, Leblanc, Ring C, Harris MA, Thompson CM. 2019. Comparison of gene expression responses in the small intestine of mice following exposure to three carcinogens using the S1500+ gene set informs a potential common adverse outcome pathway. Toxicol Pathol 47(7):851-864; doi: 10.1177/0192623319873.

Thompson CM, Wolf JC, Suh M, Proctor DM, Haws LC, Harris MA. Toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens; captan, folpet, and hexavalent chromium: Evidence for an adverse outcome pathway. Society of Toxicology Annual Meeting, San Antonio, TX, March 11-15, 2018.

Wang Y, Villalta PW, Peng L, Dingley KH, Malfatti MA, Turteltaub KW, Turesky RJ. 2017. Mass spectrometric characterization of an acid-labile adduct formed with 2-amino-1-methyl-phenylimidazo[4,5-b]pyridine and albumin in humans. Chem Res Toxicol 30(2):705–714; doi: 10.1021/acs.chemrestox.6b00426. PMID: 27984695.

Chappell G, Welsh B, Harvey S, Harris M, Wikoff D. Validation and application of a text mining tool in the identification and categorization of mechanistic data: A case study in improving problem formulation of carcinogenicity assessments. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Borghoff SJ. Organization and review of mechanistic data according to “Ten Key Characteristics of Carcinogens” (TKCC) {Smith et al., 2016}. Presented at the 42^nd Annual Summer Meeting of the Toxicology Forum, July, Salt Lake City, UT, 2016.

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Bhusari S, Malarkey DE, Hong HH, Wang Y, Masinde T, Nolan M, Hooth NJ, Lea IA, Vasconcelos D, Sills RC, Hoenerhoff MJ. 2014. Mutation spectra of Kras and Tp53 in urethral and lung neoplasms in B6C3F1 mice treated with 3,3′,4,4′-tetrachloroazobenzene. Toxicol Pathol 42(3):555–564; doi: 10.1177/0192623313491169.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG,Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90; doi: 10.1093/toxsci/kfr280.

Proctor DM, Gatto NM, Hong SJ, Allamneni KP. 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci 98(2):313–326; doi: 10.1093/toxsci/kfm075.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, et al. 2006. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 66(21):10541–10547; doi: 10.1158/0008-5472.CAN-06-1573. PMID: 17079477.

Chepanoske CL, Brown K, Turteltaub KW, Dingley KH. 2004. Characterization of a peptide adduct formed by N-acetoxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a reactive intermediate of the food carcinogen PhIP. Food Chem Toxicol 42(8):1367–1372; doi: 10.1016/j.fct.2003.11.012. PMID: 15207388.

Mally A, Zepnik H, Wanek P, Eder E, Dingley K, Ihmels H., et al. 2004. Ochratoxin A: Lack of formation of covalent DNA adducts. Chem Res Toxicol 17(2):234–242; doi: 10.1021/tx034188m. PMID: 14967011.

Turesky RJ, Richoz J, Constable A, Curtis KD, Dingley KH, Turteltaub KW. 2003. The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats. Chem-Biol Interact 145(3):251–265; doi: 10.1016/S0009-2797(03)00022-X. PMID: 12732453.